About: Clinical features and treatment of COVID‐19 patients in northeast Chongqing

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical features and treatment of COVID‐19 patients in northeast Chongqing Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical features and treatment of COVID‐19 patients in northeast Chongqing
Creator	Xiong, Yan Yang, Haoran Li, \| Lv, Jinglong Wan, Suxin Yang, \| Fang, Wei Hu, Yanjun Huang, Daoqiu Huang, \| Li, Boqun Luo, Yaling Sun, Qiuyan Zheng, \| Lang, \| Xiang, \|
source	Medline; PMC
abstract	The outbreak of the novel coronavirus in China (SARS‐CoV‐2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID‐19 were enrolled. The median age was 47 years (interquartile range, 36‐55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty‐three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d‐dimer, lactate dehydrogenase, PCT, ALB, C‐reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID‐19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID‐19.
has issue date	2020-04-01(xsd:dateTime)
bibo:doi	10.1002/jmv.25783
bibo:pmid	32198776
has license	no-cc
sha1sum (hex)	3d74fe714e3ff1217e6ba2ac689d09a2c425d417
schema:url	https://doi.org/10.1002/jmv.25783
resource representing a document's title	Clinical features and treatment of COVID‐19 patients in northeast Chongqing
has PubMed Central identifier	PMC7228368
has PubMed identifier	32198776
schema:publication	J Med Virol
resource representing a document's body	covid:3d74fe714e3ff1217e6ba2ac689d09a2c425d417#body_text
is schema:about of	named entity 'severe' named entity 'patients' named entity 'addition' named entity 'gender difference' named entity 'GraphPad Prism' named entity 'RNA' named entity 'respiratory tract' named entity 'study' named entity 'SARS-CoV-2' named entity 'symptoms' named entity 'Chest' named entity 'lung' named entity 'NK cell' named entity 'Mann-Whitney' named entity 'COVID' named entity 'mucus membranes' named entity 'epidemiological' named entity 'COVID' named entity 'COVID' named entity 'intensive care unit' named entity 'medical histories' named entity 'pneumonia' named entity 'study' named entity 'diabetes' named entity 'COVID-19' named entity 'median age' named entity 'This' named entity 'patients' named entity 'malignancy' named entity 'ground glass opacity' named entity 'antiviral therapy' named entity 'interquartile range' named entity 'SARS-CoV-2' named entity 'diabetes' named entity 'Wuhan' named entity 'computed tomography scans' named entity 'antibacterial' named entity 'Epidemiological' named entity 'Chongqing' named entity 'TCM' named entity 'disease' named entity 'northeast' named entity 'Chongqing' named entity 'neutrophil' named entity 'randomized controlled trials' named entity 'Clinical data' named entity 'CD8 +' named entity 'mm Hg' named entity 'risk factors' named entity 'coronavirus' named entity 'ICU' named entity 'mechanical ventilation' named entity 'statistically significant' named entity 'infectious disease' named entity 'aerosols' named entity '2019-nCoV' named entity 'pneumonia' named entity 'CD4' named entity 'type I error' named entity 'respiratory distress' named entity 'liver function' named entity 'Wuhan' named entity 'PCR' named entity '30 beats' named entity '8 February 2020' named entity 'feces'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software